Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Effects of a Nutraceutic Compound on Cognitive Impairment in Frailty Patients
Authors not listed
Federico II University · 2022
Abstract
The study is designed to evaluate the effects of choline bitartrate on cognitive impairment in frailty patients.
The study will analyze the impact of 4 weeks treatment randomized with a nutraceutical compound in a double-blind randomized placebo controlled trial. The investigators will also assess cognitive frailty.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-04 MST
Cite this
APA
Anonymous. (2022). Effects of a Nutraceutic Compound on Cognitive Impairment in Frailty Patients. <em>Federico II University</em>. https://clinicaltrials.gov/study/NCT06200883
Vancouver
Anonymous. Effects of a Nutraceutic Compound on Cognitive Impairment in Frailty Patients. Federico II University. 2022.
BibTeX
@misc{anon2022Effect,
title = {Effects of a Nutraceutic Compound on Cognitive Impairment in Frailty Patients},
author = {Anonymous},
journal = {Federico II University},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Neuronix Ltd 2010
Open access · US-GOV
Effects of a Combined TMS Stimulation and Cognitive Training in Alzheimer Patients: a Single-center, Randomized, Double-blind, Placebo-controlled Study
University Hospital, Lille 2021
Open access · US-GOV
Multicentre, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Effect of a 30-week Caffeine Treatment on Cognition in Alzheimer's Disease at Beginning to Moderate Stages
Memory Pharmaceuticals 2007
Open access · US-GOV
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Pharmacodynamics/Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Fixed Dosages of MEM 3454 (5 mg, 15 mg, and 50 mg) in Patients With Mild to Moderate Alzheimer's Disease
Memory Pharmaceuticals 2005
Open access · US-GOV
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease
University of California, Los Angeles 2013
Open access · US-GOV
Treatment of Geriatric Depression With Mild Cognitive Impairment: A Double-blind Placebo-Controlled Trial of Namenda (Memantine) Augmentation of Lexapro (Escitalopram) in Depressed Patients at Least 60 Years of Age
IRCCS Centro San Giovanni di Dio Fatebenefratelli 2019
Open access · US-GOV